REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.30
+0.34 (3.41%)
At close: Aug 4, 2026, 4:00 PM EDT
10.37
+0.07 (0.68%)
After-hours: Aug 4, 2026, 7:34 PM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $6.39M in the quarter ending March 31, 2026, a decrease of -92.82%. This brings the company's revenue in the last twelve months to $87.82M, down -43.96% year-over-year. In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth.
Revenue (ttm)
$87.82M
Revenue Growth
-43.96%
P/S Ratio
7.24
Revenue / Employee
$236,717
Employees
371
Market Cap
635.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| MiMedx Group | 355.17M |
| Zevra Therapeutics | 122.29M |
| Gyre Therapeutics | 117.05M |
| Crescent Biopharma | 11.88M |
| Altimmune | 36.00K |
RGNX News
- 1 day ago - REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - PRNewsWire
- 16 days ago - Regenxbio presents long-term data for surabgene lomparvovec - TheFly
- 17 days ago - REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - PRNewsWire
- 18 days ago - Regenxbio 10M share Spot Secondary priced at $9.00 - TheFly
- 18 days ago - REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - PRNewsWire
- 19 days ago - Regenxbio announces $100M common stock offering - TheFly
- 19 days ago - REGENXBIO Announces Proposed Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial - TheFly